Rezolute, Inc. (RZLT)
After hours:
- GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Completed in-vivo toxicology study in brown Norway rats; early results show no abnormalities at highest tested dose of RZ358 Continue to engage in productive interactions with FDA towards resolution of partial clinical holds and path forward for potential late-stage, registrational, clinical study in tumor hyperinsulinism (HI) REDWO
- Simply Wall St.
Rezolute, Inc. (NASDAQ:RZLT) has caught the attention of institutional investors who hold a sizeable 47% stake
Key Insights Given the large stake in the stock by institutions, Rezolute's stock price might be vulnerable to their...
- GlobeNewswire
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be
